Bosutinib inhibited 16 of 18 imatinibresistant forms of bcrabl kinase expressed in murine myeloid cell lines. Bosutinib is now in phase iii clinical trials, and phase ii studies have shown good activity in patients resistant to imatinib or other tkis. Activity of bosutinib, dasatinib, and nilotinib against. Therapeutic options against bcrabl1 t315ipositive chronic. Consequently, novel strategies are urgently needed in this setting. Characteristics and outcomes of patients with chronic myeloid.
A typeii kinase inhibitor capable of inhibiting the t315i. Efficacy and safety of bosutinib in the second and third. Bosutinib as a fourthline therapy for a patient with t315ipositive. Philadelphia chromosomepositive acute lymphoblastic. Fda approved indications bosulif is indicated for the treatment of adult patients with. Responses were seen across bcrabl mutations, including those associated with dasatinib and nilotinib resistance, except t315i. At present, more than 50 mutation sites and more than 70 individual. Here we describe a typeii t315i inhibitor 2 gnf7, based upon a 3,4dihydropyrimido4,5dpyrimidin21hone scaffold which is capable of potently inhibiting wildtype and t315i bcrabl as well as other.
Bosutinib in chronic myelogenous leukemia patients with. Also, multiple mutations causing imatinib resistance may be detected simultaneously. Bosutinib did not inhibit the t315i and v299l mutant cells. A read is counted each time someone views a publication summary such as the title, abstract, and list of authors, clicks on a figure, or views or downloads the fulltext. It has been reported that bosutinib is ineffective against t315imutated bcrabl1 in vitro 4,10,11. To our knowledge, we have been confronted with the first clinical case of a t315i clonal selection of all caused by subeffective therapeutic level of the drug. In total, 503 patients were evaluable for efficacy. Kantarjian, carlo gambacortipasserini, michele baccarani, dongwook kim, andrey zaritskey, athena countouriotis, nadine besson, eric leip, virginia kelly, tim h. Bosutinib as a fourthline therapy for a patient with. The aim of this study was to evaluate the prevalence of this mutation in bcrablpositive cml and all patients. Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients. Implications of bcrabl1 kinase domainmediated resistance in.
Pdf a t315i mutation in e19a2 bcrabl1 chronic myeloid. Ponatinib avoids the steric hindrance imposed by the threonine. Bcrabl1 mutations require consideration during secondline tyrosine kinase inhibitor selection for patients with chronic myeloid leukemia cml. In vitro testing indicated that bosutinib had limited activity against the t315i or the v299l mutation. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib andor nilotinib therapy failure. Dasatinib, nilotinib, bosutinib, ponatinib, and other tkis. Bosutinib has a unique toxicity profile that is manageable. Jul 21, 2016 the thirdgeneration tki, bosutinib, has displayed limited therapeutic potential for treating cml patients expressing somatic mutations found within the bcrabl kinase domain, specifically the t315i mutation. Bosutinib is active in chronic phase chronic myeloid. Correspondingly, the patient was revealed to carry the t315i mutation. Bosutinib is active in chronic phase chronic myeloid leukemia after. Highlights of prescribing information hepatic toxicity these highlights do not include all the information needed to use bosulif safely and effectively. The second generation of bcrabl inhibitors nilotinib, dasatinib, and bosutinib developed to override imatinib resistance are not active against the t315i gatekeeper mutation.
Request pdf chronic myeloid leukemia harboring t315i and f317l mutations successfully treated with interferon. Treating t315ipositive chronic myeloid leukemia cml. After 4 years of followup, progression to ap or bp was observed in 4% of patients on bosutinib. As reported earlier, the t315i mutation showed significant.
To determine the minimal residual disease after treatment with this combination and its impact in longterm outcome. View clinical trials for abl1 t315i abl1 t315i serves as an inclusion eligibility criterion in 5 clinical trials, of which 5 are open and 0 are closed. A new bcrabl1 mutation l248r is highly resistant to imatinib, bosutinib, nilotinib and dasatinib, but can be inhibited by ap24534 and dcc2036. The most important mutations are the ploop mutations and the t315i mutation. Bosutinib and dasatinib have similar but not identical profiles. Specifically, bosutinib has been shown to inhibit 16 of 18 imatinib gleevec, novartisresistant forms of bcrabl expressed in murine myeloid cell lines, with no observed inhibition of t315i and v299lmutant cells. Relapse occurred in 8 of the patients with the t315i mutation, and 2. Bosutinib is an oral formulation to be taken once daily with food. Characteristics and outcomes of patients with chronic myeloid leukemia and t315i mutation following failure of imatinib mesylate therapy. Phase iii study of bosutinib in combination with inotuzumab. However, axitinib, a vascular endothelial growth factor receptor inhibitor, is effective against this mutation.
Bosutinib is not active against the t315i mutation. The t315i imatinib resistance mutation has also been found to confer resistance to bosutinib. In this study, we investigated axitinib activity against ponatinibresistant cells and found that axitinib inhibited cellular growth and apoptosis in baf3 t315i mutant. Bosutinib effectively overcomes the majority of imatinibresistanceconferring bcrabl mutations except v299l and t315i. As evidenced by the median dose intensity of treatment within the clinical trial setting, bosutinib appears to be welltolerated. Bosutinib inhibits the bcrabl kinase that promotes cml.
Antileukemic activity of axitinib against cells harboring. A new bcrabl1 mutation l248r is highly resistant to. F311l, m351t, and t315i and all patients with preexisting bcrabl mutations exhibited imatinib resistance 33. Among these mutations, y253h, e255k, t315i, and m315t are observed more frequently. When multiple mutations are detected, mutations may be present in different bcrabl molecules polyclonal mutation or in a single. Treatment of chronic myeloid leukemia in chronic phase after. Bosutinib works on a large number of singlepoint resistance mutations induced by the firstgeneration drugs in the absence of the gatekeeper mutation t315i. Sara redaelli, luca mologni, roberta rostagno, rocco piazza, michela viltadi, scott wise, daniel flynn, carlo gambacortipasserini. Patients with t315i mutations are excluded due to the lack of activity of bosutinib against this gatekeeper mutation. It has been reported that bosutinib is ineffective against t315i mutated bcrabl1 in vitro 4,10,11. Bosutinib as a fourthline therapy for a patient with t315i. Bcrabl point mutations and tki treatment in cml patients. Ponatinib thwarts t315i gene mutation in chronic myeloid leukemia november 29, 2012, news medical analysis of mutations in the bcrabl1 kinase domain, using direct sequencing.
Activity of bosutinib, dasatinib, and nilotinib against 18. Bosutinib ski606 is an oral, dualcompetitive src and abl tyrosine kinase inhibitor tki approved for adult cml patients resistant or intolerant to prior therapy. That really drives treatment choice, currently, and points us towards one agent, ponatinib. Dasatinib axitinib nilotinib ponatini b imatinib bosutinib atp table 1. Iclusig ponatinib, previously known as ap24534 is an orally active multityrosine kinase inhibitor and is currently approved by the us food and drug administration for patients with chronic myeloid leukemia and philadelphia chromosomepositive acute lymphoblastic leukemia, specifically targeting the bcrabl gene mutation, t315i. If your cml stops responding to treatment with a tki, another one may be tried.
As imatinib, nilotinib, dasatinib and bosutinib are not effective against the t315i mutation, treatment choices for patients with t315i mutations are very limited. We analyzed 27 patients with t315i, including 20 who developed t315i after imatinib failure representing 11% of 186 patients with imatinib failure, and 7 of 23 who developed new mutations after second tyrosine kinase inhibitor tki. While ponatinib ap24534, iclusig targets the t315i mutation, vascular toxicities limit its usage. E255kv, f359vci, and t315i, and bosutinib v299l and t315i. The structural constraints posed by this mutation are believed to be responsible for the lack of activity of other atpcompetitive tkis such as nilotinib, dasatinib, bosutinib, and inno406 against bcrabl1 t315i positive cells 2226. Bcrabl1 mutation analysis for tyrosine kinase inhibitor. In addition, in phase 1 and 2 clinical trials, cmlcp patients with the t315i mutation exhibited poor responses compared to those without the mutation 1517. Chronic myeloid leukemia harboring t315i and f317l. T315i is one of the most common acquired mutations in this domain, which occurs in atp binding site and inhibits the formation of hydrogen bond with im.
Therefore, clinical activity in patients with these mutations is. The role of bosutinib in the treatment of chronic myeloid leukemia. Highlights of prescribing information hepatic toxicity. Apr 28, 2017 posts about t315i mutation written by kris griffin. Ponatinib iclusig by ariad was approved in 20 for use as secondline cml treatment, and is the only licensed tki which binds to the t315i mutated kinase successfully. Mutations on other sites of the kinase have also been reported, for example on the chelix, sh2 domain, substrate binding site, activation loop and cterminal lobe. In the bosutinib efficacy and safety in chronic myeloid leukemia bela trial, bosutinib attained a faster and deeper molecular response than imatinib in newly diagnosed chronicphase chronic myelogenous leukemia patients. As was mentioned in the section about targeted therapy, in some patients on tki treatment, the cancer cells develop a gene change called the t315i mutation that keeps most of the tkis from working. The initial treatment of chronic phase cml and specific details regarding the pharmacology of tkis are discussed separately. The most common mutations with imatinib were t315i, g250e, m244v. Bosutinib is an orally bioavailable srcabl tyrosine kinase inhibitor with activity against all phases of resistant chronic myeloid leukemia that do not express the t315i or v299l abl kinase domain mutations. This is a phase i, doseescalation study of bosutinib followed by a phase ii. T315i produces the highest magnitude of resistance of any mutation both to imatinib and second generations tkis. Bosutinib is active in chronic phase chronic myeloid leukemia.
Dec 27, 2018 bosutinib is an oral, secondgeneration bcrabl1 tyrosine kinase inhibitor tki. Pdf prevalence of bcrabl t315i mutation in malaysian. In the secondline setting, bosutinib is effective in some patients with cml resistant or intolerant to imatinib, dasatinib, andor nilotinib, but it is not effective in patients whose disease expresses the t315i point mutation in bcrabl. Single mutations highly resistant to dasatinib, nilotinib, and bosutinib were more frequent. Request pdf on jan 20, 2009, sara redaelli and others published activity of. To determine the efficacy of this combination according to pretreatment mutation status in the abl kinase domain. In distinction to other similar inhibitors, bosutinib does not inhibit the plateletderived. Bosutinib bosulif national drug monograph october 2015.
Mutation t315i chronic myeloid leukemia cml chronic. Comparison of frequency and sensitivity of bcrabl1 kinase. Jorge cortes, a renowned expert on cml and chair of the cml section at md anderson center explains the latest news on existing and emerging treatments. Treatment of chronic myeloid leukemia in chronic phase. Synergism between bosutinib ski606 and the chk1 inhibitor. Bosutinib also has been compared with imatinib, the standard firstline treatment, in 502 patients with.
The bcrabl1 t315i mutation affects a highly conserved threonine residue close to the catalytic domain of the enzyme and confers insensitivity to imatinib and the second generation tkis nilotinib, dasatinib, and bosutinib 2226. A combined computational and experimental strategy. Chronic myeloid leukemia cml with t315i mutation has been reported to have poor prognosis. Patients harboring t315i mutations should be treated with ponatinib, as this mutational profile is resistant to all other bcrabl1 tkis 3,4,58,66. Optimizing kinase inhibitor selection for cml patients. T315i mutation of bcrabl1 into human philadelphia chromosomepositive leukemia cell lines by homologous recombination using the crisprcas9 system. Patients with a documented history of bcrabl1 t315i mutation could enter the study until an amendment may 28, 2008 made such patients ineligible. The t315i mutation has been reported to occur in f15% of. Imatinib, bosutinib, and nilotinib presented one highly resistant mutant in addition to the t315i v299l for bosutinib and e255v for imatinib and nilotinib, whereas dasatinib showed a high rr only against t315i. This clonal evolution was reversed, without adverse effects, by increasing ponatinib to 45 mgday. Bosutinib was first approved in 2012 for treatment of chronic, accelerated, and blastphase cml in patients previously treated with one or more tkis and for whom imatinib, nilotinib, and dasatinib are not considered appropriate treatment options or in patients resistant or intolerant to prior therapy, according. Prevalence of bcrabl t315i mutation in malaysian patients with imatinibresistant chronic myeloid leukemia.
To our knowledge, we present here the first comprehensive characterization of bosutinib, tested against 18 imatinibresistant bcrabl mutants and compared with dasatinib and nilotinib. Bosutinib is a very effective tki against all phases of intolerant or resistant cml regardless of the presence or absence of an abelson gene domain mutation, except for cases with detectable t315i. Oct 09, 2017 bosutinib in chronic myeloid leukemia. To our knowledge, we have been confronted with the. The present retrospective analysis compared the frequency of bcrabl1 mutations in asian and white patients in whom imatinib therapy had failed. Now that three tkis imatinib, dasatinib, and nilotinib are approved firstline options. Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy. New directions in the management of chronic myeloid leukemia. Of the trials that contain abl1 t315i as an inclusion criterion, 1 is phase 1 1 open, 2 are phase 1phase 2 2 open, and 2 are phase 2 2 open. Inotuzumab ozogamycin is administered by iv infusion over 1 hour on days 1, 8 and 15. The t315i mutation is of special interest as it continues to be an obstacle to the use of tkis. Here we describe a typeii t315i inhibitor 2 gnf7, based upon a 3,4dihydropyrimido4,5dpyrimidin21hone scaffold which is capable of potently inhibiting. Therapeuticoptionsagainst bcrabl1 t315ipositivechronic.
While bosutinib, like the three currently approved inhibitors of bcrabl, is inactive against the common t315i mutation, our results suggest that the related 4anilinoquinazolines are not affected by this mutation, and might yield an effective remedy for this form of bcrabl. Originally synthesized by wyeth, it is being developed by pfizer. New directions in the management of chronic myeloid. It is active against various bcrabl1 mutations, including those associated with imatinib, dasatinib and nilotinib resistance. Characteristics and outcomes of patients with chronic myeloid leukemia and t315i mutation following failure of imatinib mesylate therapy article pdf available in blood 1121. The structural constraints posed by this mutation are believed to be responsible for the lack of activity of other atpcompetitive tkis such as nilotinib, dasatinib, bosutinib, and inno406 against bcrabl1 t315ipositive cells 2226. Structural and spectroscopic analysis of the kinase inhibitor. Other mutations may point towards or away from other medications. Ponatinib, a thirdgeneration tki, was specifically designed to inhibit bcrablpositive cml cells containing the t315i mutation. See initial treatment of chronic myeloid leukemia in chronic phase and overview of the treatment of chronic myeloid leukemia and clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia. Impact of bcrabl mutations on patients with chronic myeloid. Response rates in patients with an identified mutation of the bcrabl1 at baseline n 115 and in patients without any mutation were similar, with the exception of t315i mutation which is insensitive to bosutinib.
Bosutinib in the treatment of chronic myelogenous leukemia. Retrospective bcrabl1 t315i allelespecific oligonucleotide aso realtime quantitative polymerase chain reaction rqpcr was performed on the pretreatment samples of 43 patients, of whom 10 23% tested positive for the t315i mutation. Factors influencing longterm efficacy and tolerability of. Novel therapies for t315imutant chronic myeloid leukemia. There are no comparative trials of bosutinib, nilotinib, or dasatinib in the secondline setting. The bosutinib dose is escalated from 300 to 500 mg daily in the phase i portion. And one of the most important, again, is the t315i mutation. Management of adverse events associated with bosutinib. A t315i mutation in e19a2 bcrabl1 chronic myeloid leukemia responding to dasatinib article pdf available in leukemia research 349. There are mutations that are particularly sensitive to erlotinib and are resistant to dasatinib and bosutinib, for example.
127 77 1604 294 1180 613 1412 872 177 897 1044 558 1478 1479 152 887 710 657 898 500 298 994 600 648 1074 923 1134 150 1604 990 432 1131 355 722 458 142 599 1128 626